Myomo Inc.
This article was originally published in Start Up
Executive Summary
Myomo is capitalizing on the growing tide of scientific evidence that patients have the ability to recover motor function following neurological trauma, such as stroke. The first product from its NeuroRobotics platform is the e100 NeuroRobotic System, a lightweight robotic brace that slides onto the arm and helps improve the patient's mobility by enabling him to initiate and control movement of partially paralyzed muscles by using his own biological signals.
You may also be interested in...
Start-Up Previews
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Targeted Cancer Therapeutics," features profiles of Coronado Biosciences, Emiliem and SynDevRx. Plus these Start-Ups Across Health Care: Activaero, Chakshu Research, Myomo and Valor Medical.
Start-Up Previews
A preview of the emerging health care companies profiled in the current issue of Start-Up. This month's profile group, "Targeted Cancer Therapeutics," features profiles of Coronado Biosciences, Emiliem and SynDevRx. Plus these Start-Ups Across Health Care: Activaero, Chakshu Research, Myomo and Valor Medical.
Striking Out Against Stroke
Predicting, preventing, and treating stroke has always been challenging for drug and device developers. The sheer number of potential patients and the current scarcity of safe and effective treatment options make this one of the most intriguing markets. Innovation in the device arena continues at a slow but steady pace, and clinicians and patients are beginning to reap the benefits of recent advances.